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Epidemiological as well as in vitro studies generally support a beneficial 
effect for consumption of fruits and vegetables in prevention of prostate cancer. This 
leads to the hypothesis that phytochemicals in fruits and vegetables may contribute to 
cancer preventive effects. Resveratrol, a phytoalexin, has been proposed as a prostate 
cancer preventive candidate. However, relatively little is known of the molecular 
targets in prostate cell as well as mechanisms that may contribute to the prevention of 
prostate cancer. This thesis attempted to elucidate the molecular effects of resveratrol 
and the mechanisms underlying the prostate cancer preventive effect of this 
compound. 
 
Our results indicated that resveratrol exerts inhibitory effects on the growth of 
androgen responsive human prostate cancer cell, LNCaP. The effects of resveratrol 
  
correlate with the activation of the p53-dependent pathway and the inhibitory effect 
on hormonal-mediated effects. At the molecular level, we found resveratrol inhibited 
androgen-responsive genes (ARGs) through both androgen- and estrogen-mediated 
events. Moreover, resveratrol also regulates the IGF-1 pathway through regulation of 
androgen- and estrogen-mediated events. These results provide the molecular basis to 
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Chapter 1: Introduction 
According to American Cancer Society statistics for 2006, prostate cancer is 
the most frequently diagnosed cancer, and is a leading cause of cancer death in men 
in the US (1).  Surgery and external beam radiation or radioactive seed implants may 
be used to treat early-stage disease. Androgen ablation therapy, chemotherapy, and 
radiation are used for metastatic disease (1). Hormonal therapy can control prostate 
cancer for long periods by shrinking the size of the tumor, but tumors often become 
androgen-independent, leading to a relapse within 2 years (2). Because there is no 
complete cure for prostate cancer, many current research efforts are focused on 
preventive approaches that reduce disease incidence. Bioactive food components are 
increasingly being evaluated as potential prostate chemopreventive agents (3, 4). One 
such agent is resveratrol, a phytochemical which has been considered as a 
chemopreventive for human prostate cancer (5, 6). 
 
Since Pezzuto et al. (7) published a paper of cancer chemopreventive activity 
of resveratrol in Science in 1997, interest in the plant-derived chemical, resveratrol 
(Figure 1), has exploded over the last few years (Figure 2) and continues to increase 
due to a wealth of data suggesting that resveratrol possesses as potent and wide-range 
of biological effects (8-10). Its beneficial effects include prevention of breast and 
prostate cancers, as well as lowering the risk of cardiovascular disease (11). However, 
the molecular mechanisms underlay the beneficial effects of resveratrol on prevention 
of cancer, such as prostate cancer, remain largely unknown. Hence, to fully realize 




elucidate the molecular effect and mechanism of action of resveratrol on cells would 
be the critical first step. This thesis seeks to address this question.  
 
Base on published literatures, this thesis tested the hypothesis that resveratrol 
can modulate multiple pathways that are important in prostate cancer development. In 
the following chapters, experiments were designed to study effects of resveratrol 
through three possible mechanisms: androgen-mediated pathway, estrogen-mediated 
























































Figure 2. Number of research articles published from 2001 to 2005, relative to resveratrol. A search 

















In chapter three, we explored the effect on androgen receptor (AR) as one 
possible mechanism for resveratrol on prostate cancer prevention. Previous studies 
have shown that resveratrol decreases expression of prostate-specific antigen (PSA) 
(12). Androgen is known to act through AR (13). This suggests that the effects of 
resveratrol may be mediated by the AR pathway. In this study, we demonstrated that 
resveratrol has an effect on multiple genes belonging to the AR-dependent pathway. 
Moreover, we also provide data to support that resveratrol modulates the ARG 
expression not only through the AR but also through the ER-mediated pathway. 
These results provide support for our hypothesis that resveratrol modulates multiple 
pathways that impact prostate cancer development, and the prostate cancer preventive 
effects of resveratrol may partially mediate through androgen and estrogen dependent 
signaling. 
 
In addition to the androgen and estrogen pathways, there are other possible 
pathways influenced by resveratrol in which may contribute to prostate cancer 
prevention. In chapter four, we demonstrated that resveratrol can inhibit the 
expressions of the IGF-1 and IGF-1R at the mRNA level. IGF-1 exerts its effects 
through IGF-1R and is known to stimulate prostate cancer cells and is associated with 
an increased risk of prostate cancer (14). Thus, modulation of IGF-1 pathway may 
also contribute to resveratrol’s prostate cancer preventive effects. 
 
Based on the results present in this thesis, we concluded that the inhibitory 
effects of resveratrol on the growth of prostate cancer cell maybe mediated through 




resveratrol on normal prostate cells; 2) effect of resveratrol on AR-independent cells; 
and 3) an animal study to demonstrate AR, ER, and IGF pathways of resveratrol in 





















Chapter 2: Literature Review 
2.1 Resveratrol  
2.1.1 General Information about Resveratrol 
Trans-resveratrol was first detected in grapevines (Vitis viniferu) in 1976 by 
Langcake and Pryce (15). These investigators using GLC-MS method found that 
resveratrol was synthesized by leaf tissues in response to fungal infection (mainly 
Botrytis cinereu) or exposure to ultraviolet light.  
 
It is now well documented that trans-resveratrol (3, 4’, 5 trihydroxystilbene) 
(Figure 1) is a phytoalexin produced by spermatophytes, such as grapevines, in 
response to injury (11). For example, in response to an invading fungus, resveratrol is 
synthesized by plants from p-coumaroyl CoA and malonyl CoA  to repel the invading 
fungus (16).  
 
2.1.2 Sources  
Resveratrol is commonly found in Polygonum cuspidatum roots, but it is also 
presented in other plants such as eucalyptus, spruces, and lilies, as well as in common 
foods such as mulberries and peanuts (11).  The most abundant natural sources of 
resveratrol are Vitis vinifera, Vitis labrusca, and Vitis rotundifolia grapes, which are 
used to make wines (11).  Resveratrol exists in the grapevines, roots, seeds, and 
stalks, but the highest concentration is in the skin of grapes (17), which contains 50-




The resveratrol content of wine is related to the length of time during the 
fermentation process with grape skin.  Because the skins are removed during white 
wine production, the concentration of resveratrol in red wine is significantly higher 
than the concentration of resveratrol in white wine (17). A fluid ounce of red wine 
averages 160 µg of resveratrol. Other foods contain less resveratrol. For example, 
edible peanuts only contain an average of 73 µg resveratrol per ounce (19). 
 
Table 1. The content of resveratrol in foods 




Red wines Peanuts 
(Boiled) 











2.1.3 Resveratrol Bioavailability 
Resveratrol can be absorbed and metabolized by humans and 75% of 
resveratrol is excreted via feces and urine (20).  In human serum, the major form of 
resveratrol is trans-resveratrol glucuronides, rather than the free form of the 
compound (21). After administering a dose of 360 µg/kg body weight resveratrol 
either dissolved in grape juice, vegetable juice, or white wine, the plasma peak 
concentration of resveratrol can reach 20nM free form of resveratrol and 2µM total 





Studies in mice, rats, and dogs suggest that resveratrol is well absorbed and 
rapidly glucuronidated and sulfated both in the liver and intestinal epithelial cells 
(23).   Most importantly, peak plasma level of 6.6 µM unmetabolized resveratrol in 
the rat can be reached after a high oral dose of 50 mg/kg (24). However, it is 
eliminated rather rapidly (24). In contrast, glucuronidated resveratrol seems to reach 
much higher plasma levels than the unmetabolized resveratrol (24). 
 
2.1.4 Biological Activities of Resveratrol  
Resveratrol appeared to possess various biological activities. As mentioned 
above, resveratrol is synthesized in Polygonum cuspidatum roots.  Polygonum 
cuspidatum roots have been used in traditional Asia oriental medicine (18). As a 
phenolic compound, resveratrol appears to contribute to the antioxidant potential of 
red wine and thereby may play a role in the prevention of human cardiovascular 
diseases (25). Resveratrol has been shown to modulate the metabolism of lipids, and 
to inhibit the oxidation of low-density lipoproteins and the aggregation of platelets 
(9). Hence, resveratrol may provide cardiovascular protection (26).  Resveratrol also 
appears to possess anti-inflammatory and anticancer properties (8, 27). The biological 
activity of resveratrol related to cancer will be discussed in detail as follow. 
 
2.2 Resveratrol and Cancer Prevention 
Cancer development can be divided roughly into three stages: initiation, 




mutagenic event that produces a cell with altered genetic code with advanced growth 
characteristic.  The second stage, tumor promotion, is a slow and reversible, 
epigenetically controlled clonal expansion of the initiated cell that produces a benign 
tumor. Tumor progression is the irreversible conversion of the benign tumor to a 
malignant phenotype. 
 
The effects of resveratrol on cancer have been explored (10). Resveratrol 
appeared to affect initiation, promotion as well as progression of cancer. These effects 
are described as follow. 
 
2.2.1 Antioxidant Effects of Resveratrol 
Tumor initiation is considered due to DNA damage (28, 29).One possible 
route is the control of reactive oxygen spices (ROS) in cells (30). Several studies have 
been conducted to examine the effect of resveratrol on initiation of cancer (31).  At 
the level of tumor initiation, resveratrol appeared to act as an antioxidant by inhibiting 
free radical formation, and thus as an anti-mutagen (7).   
 
The anti-tumor initiating activity of resveratrol may be attributed its ability to 
control ROS (32). Sharma et al. (33) reported that resveratrol inhibited, in a dose-
dependent manner, free-radical formation (ED50 = 27 µM) when human 
promyelocytic leukemia (HL-60) cells were treated with 12-O-tetradecanoylphorbol-
13-acetate (TPA). Stojanovic et al. (34) found resveratrol acts as a free radical 




inhibited the production of H2O2 and myeloperoxidase activity while it restored the 
cellular glutathione levels and the activity of superoxide dismutase (35).  Cadenas and 
Barja (36) demonstrated that resveratrol effectively prevented oxidative damage in 
the renal DNA of rats treated with the kidney-specific carcinogen KBrO3 (36). 
 
2.2.2 Stimulation of Detoxification Enzymes by Resveratrol 
In addition to scavenging reactive oxygen species, resveratrol may also turn-
on de novo synthesis of genes encoding detoxification (37). Incubation of H9C2 cells, 
mouse hepatoma cells, with 25–100 μM resveratrol resulted in a marked enhancement 
in the activity of a phase II metabolizing enzyme NAD(P)H:quinone oxidoreductase 
in a concentration- and time-dependent manner, thereby stimulating detoxification of 
carcinogens (7, 38, 39). Likewise, resveratrol caused induction of NAD(P)H:quinone 
oxidoreductase, 10 μM resveratrol completely inhibited, in a concentration-dependent 
manner, the activity of the carcinogen activating enzymes cytochrome P450 
(CYP)1A1/CYP1A2 induced by benzo[a]pyrene, an environmental aryl hydrocarbon, 
in microsomes and intact HepG2 cells. (40). CYP450 isozymes are a large family of 
detoxifying enzymes that play important roles in the metabolism of carcinogens (41). 
The metabolites from CYP catalyzed reaction generally activate the pro-carcinogens 
resulting in carcinogens that interact with the DNA of target cells (42). Resveratrol’s 
inhibitions of CYP 1A1 and CYP1B1 are consistent with decreased pro-carcinogen 





2.2.3 Anti-inflammatory and Anti-tumor Promoting Effects of 
Resveratrol 
The promotional stage of carcinogenesis has been proposed as a reversible 
process that involves changes in cellular signal transduction cascades. This leads to 
abnormal expression of genes involve in the regulation of cellular proliferation and 
growth (32). Because of the causal relationship between inflammation and tumor 
promotion, enzymes that mediate the proinflammatory process, such as 
cyclooxygenase (COX)-2 and inducible nitric oxide synthase (iNOS), have been 
implicated in the pathophysiology of certain types of human cancers (43).  Thus, 
substances with potent anti-inflammatory activities are anticipated to exert 
chemopreventive effects, particularly in the promotion stage.  
 
Resveratrol has been reported to inhibit TPA-induced COX-2 when treated 
mouse with 25 μmol resveratrol in 200 μl acetone per mouse on dorsal skin in 
transcription level (44). In F344 rat study, N-nitrosomethylbenzylamine (NMBA)-
induced up-regulated both COX-1 and COX-2 mRNA expression were decreased by 
administering resveratrol at 1–2 mg/kg in NMBA-induced esophageal tumor tissues 
(45). Resveratrol, in a dose-dependent manner, inhibited phorbol ester-mediated 
induction of COX-2 activity significantly from 2.5 μM in human mammary and oral 
epithelial cells (46).  Moreover, resveratrol was reported to significantly inhibit the 
expression of COX-2 without changing the COX-1 level in the rat colonic 
inflammation induced by trinitrobenzenesulfonic acid (47). Inhibition of COX-2 may 
account for resveratrol’s anti-tumor promoting effect. Topically applied resveratrol 




further supported the anti-tumor promoting potential of resveratrol (48). In addition, 
the anti-tumor promotional effects of resveratrol may also be related, in part, to its 
ability to enhance or restore gap-junctional intracellular communication in cells 
exposed to tumor promoting agents (49).  
 
 2.2.4 Induction of Apoptosis by Resveratrol 
Apoptosis represents an important cellular protective mechanism against 
neoplastic transformation, eliminating a damaged cell or repressing the outgrowth of 
transformed cells (50).  Since disruption of apoptosis promotes survival and 
outgrowth of damaged or initiated cells, suppression of this physiologic phenomenon 
may result in non-genotoxic carcinogenesis (51).  Therefore, induction of apoptosis in 
precancerous or malignant cells is considered as another promising strategy for 
chemoprevention (52).  
 
Resveratrol has been shown to trigger apoptosis in various transformed or 
malignant cell types by activating tumor suppressor protein p53 and specific caspases, 
stimulating cytochrome c release, up-regulating pro-apoptotic Bax or down-
regulating anti-apoptotic Bcl-2 (53).  A p53-dependent mechanism for resveratrol-
induced apoptosis has been demonstrated. According to Huang et al. (54), resveratrol 
induced apoptosis of human embryonic fibroblasts that express wild type p53 in a 
dose-dependent manner in the range 2.5–40 µM , but not in p53 deficient cells (54). A 




of p21 was suggested as a mechanism by which resveratrol induced apoptosis in Hep 
G2 cells at 10 μg/ml (~44 μM; 55). Zhou et al. (56) demonstrated that 10 μM 
resveratrol induced apoptosis in human esophageal cancer cells through down-
regulation of Bcl-2 and up-regulation of Bax. Surh et al. (57) also have found that 
resveratrol-induced apoptosis in human promyelocytic leukemia cells by 
internucleosomal DNA fragmentation and decreased expression of Bcl-2. The 
mechanisms by which resveratrol induces apoptosis in various cancer cells appear to 
be cell type-specific only in p53-dependent cells but not in p53-independent cells 
(55).   
 
2.2.5 Regulation of Cell Cycle Progression by Resveratrol 
Besides induction of apoptosis, cell cycle arrest is another feature of many 
effective chemopreventive agents (58). Cell cycle is controlled by cyclin dependent 
kinases (CDKs) which are composed of two proteins, a cyclin and a kinase (59). Cell 
cycle progression can be halted at several points by the tumor suppressor genes 
through modulation of these CDKs as a result of activation in response to checkpoints 
sensing DNA or chromosome damage (60). If loss of cell cycle regulation occurred in 
an organism, it can lead to cancers (61). Any mutation that removes or otherwise 
modifies a checkpoint inhibitor (such as p53) or removes or modifies a transcription 
inhibitor (such as Rb) will lead to a loss of cell cycle regulation and lead to cancer 
(62). The roles of the G1 to S and the G2 to M transition and the corresponding 





Accumulating data from various in vitro studies indicate that resveratrol 
possesses strong anti-proliferative properties. Resveratrol prevented proliferation of 
tumor cells by inhibiting DNA synthesis with a IC50 value of 8–10 μM in both murine 
mastocytoma P-815 cells and human myelogenous leukemia K-562 cells  (64) and 
interfering with various stages of cell cycle progression (58). A number of studies 
reported that a variety of different human cancer cell lines, treated with resveratrol, 
arrested cell cycle in the G1/S boundary (65), in the S phase (66, 67),or in the G2/M 
phase (68, 69) . By using FACS, Joe et al. (70) have found resveratrol (300 µM) can 
induce S phase-arrest in breast cancer, liver cancer, colon cancer, esophageal cancer 
cell lines(70). 
   
2.2.6 Resveratrol as Phytoestrogen and Antiestrogen 
Resveratrol appears to possess estrogen-like activity and is often referred to as 
phytoestrogen.  Estrogens, produced in ovaries and testis, have many biological 
effects in the body beyond the reproductive system (71) .  Estrogen acts through the 
estrogen receptors (ERs) to exert its biological activity (71) . The estrogen receptors 
are localized in the nucleus and formed dimer when bound to an estrogen (71).  The 
dimer then interacts with the Estrogen Response Element (ERE), which regulates 
transcription of estrogen responsive genes (71). Resveratrol was shown to bind to ER 
in cytosolic extracts from MCF-7 and rat uteri (72). It appeared to have a greater 
affinity for the beta form of ER (ERβ) than the alpha form of ER (ERα) (73). 
Moreover, resveratrol also exhibits antiestrogenic activity and appears to inhibit the 




2.2.7 Resveratrol and Prostate Cancer  
Prostate cancer remains one of the most common malignancies in Western 
countries and is also increasing in Asian countries (75). It is the second leading cause 
of cancer deaths among American men (76). There are three established risk factors 
for prostate cancer: age, ethnic group, and family history (77). In addition, exposure 
to androgen is also a well documented risk factor for prostate cancer. Other hormone 
may also influence prostate cancer development, such as estrogen and IGF-1. It was 
also shown that 10 nM R1881, a synthesized androgen, can up regulate the insulin-
like growth factor 1 receptor (IGF-1R) expression on prostate cancer, both LNCaP 
and PC3 (78), and it has been shown consistently that high levels of the circulating 
insulin-like growth factor 1 (IGF-1) are associated with an increased risk of prostate 
cancer (79). Thus, IGF-1 pathway may be involved in prostate carcinogenesis. 
Estrogen is another steroid hormone which has evidence in prostatic carcinogenesis 
(80). Estrogen has been shown to possess the ability to influence androgen-response 
gene expression (81). 
 
Diet is one of possible factors that may influence the incidence of prostate 
cancer (4, 82). Various phytochemicals, such as genistein, lycopene, and sulforaphane, 
have been proposed to contribute to the prevention of prostate cancer (83). Among 
the phytochemicals, resveratrol has been proposed to be a candidate compound for 
prostate cancer prevention (5). The following sections review the effect of resveratrol 





2.2.7.1 Inhibition of Multistage Carcinogenesis 
For the initiation, the first approached stage for the cancer prevention, of 
prostate cancer, resveratrol has been found to act as an antioxidant and prevent 
oxidative DNA damage (84). Many studies have found resveratrol can inhibit the 
prostate cancer cell growth by inhibition of cell cycle (85) and induction of apoptosis 
(86). For the cell cycle, Morris et al. (87) have found that resveratrol can inhibit both 
LNCaP cell, an androgen responsive prostate cancer cell, and DU145, an androgen-
unresponsive prostate cancer cell growth, by induction of apoptosis when treated cells 
with 100 μM of resveratrol for 72 hours (87). Kumajerwala et al. (88) also found that 
resveratrol induced the prostate LNCaP cancer cells to enter the S phase and inhibited 
the DNA synthesis at concentrations above 15 µM (88).  For the induction of apoptosis 
in prostate cancer cell, DU 145 cells were treated with resveratrol and apoptosis was 
measured by determining nucleosome content, and resveratrol has been found to 
induce serine phosphorylation of p53 and activate apoptosis in a mutant p53 prostate 
cancer cell line (89). 
 
2.2.7.2 Inhibition of Androgen-Dependent Signaling by Resveratrol 
Androgens stimulate proliferation and impede apoptosis of normal prostate 
epithelial cells as well as androgen-responsive prostate cancer cells (90).  The 
efficiency of androgen ablation in the treatment of hormone-dependent metastatic 
prostate cancer is largely resulted from the induction of apoptosis of neoplastic 




(91). The neoplastic cells are susceptible to apoptosis upon androgen withdrawal 
whether dormant or proliferating; this is highly significant in light of the low 
proliferative index characteristic of neoplastic prostate disease (91). Thus, compounds 
that modulate androgen-mediated pathway may be potentially effective 
chemopreventive agents. 
  
Mitchell et al. (92) showed that resveratrol has anti-androgenic effects at 100 
μM in the androgen-dependent human prostate cancer cell line, LNCaP (92). They 
found repression of AR expression, the AR-specific co-activator ARA70 and PSA. 
These effects of resveratrol on AR-dependent pathway correlated with cell-growth 
suppression and induction of apoptosis by resveratrol (92).  In a related study, Hsieh 
& Wu (12) also found that 25 μM resveratrol can suppress PSA expression in LNCaP 
cells. However, they did not detectably alteration in AR expression (12).  Together, 
these studies provide evidence that resveratrol may antagonize androgen action in 
prostate cancer cells but the precise mechanism remains unclear.  These findings also 
offer preliminary evidence that cancer preventive properties of resveratrol may 






 2.2.7.3 Inhibition of Androgen-Independent Proliferative Signaling by 
Resveratrol 
It is almost without exception that after the androgen ablation therapy of 
hormone-refractory metastatic prostate cancer, a more aggressive, hormone-
unresponsive prostate cancer will appear (91).   
 
As mentioned before, prostate cancer cell's hormone responsive status may 
also influence the response to resveratrol (93). The growth of DU-145, androgen-
insensitive human prostate cancer cell, is inhibited by resveratrol through 
phosphorylation of p53 at serine 15 residue. This effect, accompanied by the 
activation of MAPKs, leads to enhanced p53 DNA binding (94). By using flow 
cytometric analysis, Hsieh et al. (86) showed that resveratrol (50-100 μM) partially 
disrupts the G1/S transition in three androgen-nonresponsive prostate cancer cell lines. 
Moreover, Hsieh et al. (86) also found that resveratrol-induced apoptosis of DU-145 
cells was mediated by blocking the expression of the heat shock protein 70 at 50-100 
μM. 
 
2.2.8 Hypothesis of Thesis  
The documented effects of resveratrol on multistage carcinogenesis as well as 
in vitro effects on prostate cancer cell have prompted proposal of resveratrol as a 




resveratrol action in prostate cancer cells remain unclear. The current thesis seeks to 
address this question. Based on available literatures, we hypothesized that 
1) Resveratrol modulates multiple pathways in prostate cancer cells. 
2) The growth inhibitory effects of resveratrol are mediated in part through 
modulation of AR-mediated pathway. 
3) In addition to androgen, modulation of ER- and IGF-1- mediated events 
by resveratrol may also contribute to the prostate cancer preventive effects 




Chapter 3: Resveratrol Modulates Androgen Responsive 
Genes through Both the Androgen Receptor and the 
Estrogen Receptor Pathways in the Androgen Responsive 
Cell LNCaP 
3.1 Abstract  
Resveratrol is a phytochemical that has been considered for use as a prostate 
cancer chemopreventive agent. This study examines the mechanism by which 
resveratrol modulates gene expression in LNCaP prostate cancer cells. Expression of 
androgen- and estrogen-regulated genes was measured in LNCaP cells cultured in the 
presence or absence of hormonal stimulation and the presence or absence of 
resveratrol. The results show that resveratrol suppresses expression of androgen-
responsive genes including PSA and Ste20-related proline-alanine rich kinase 
(SPAK) in LNCaP cells grown in 10% FBS. However, resveratrol has little or no 
effect on basal expression of β-2 microglobulin (B2M) and selenoprotein P (SEPP1) 
under same cell growth conditions.  LNCaP cells cultured in the presence of R1881, a 
synthesized androgen, expressed high levels of PSA, SPAK, B2M and SEPP1. The 
R1881-induced expression of these genes is uniformly blocked by resveratrol. For 
PSA and SPAK, resveratrol also blocks or down-regulates E2-induced transcription.  
These results indicate that resveratrol selectively alters the expression of ARGs in 
LNCaP cells, by modulating both androgen- and estrogen-induced signaling pathways 





Prostate cancer is the second leading cause of cancer death in American men 
(95). Conventional therapy and surgical approaches have not significantly reduced the 
incidence, morbidity or mortality associated with this cancer. Androgen deprivation 
therapy for metastatic prostate cancer has been used to delay disease progression, but 
tumors often become androgen-independent, leading to a relapse within 2 years. 
Because there is no effective cure for prostate cancer, many current research efforts 
are focused on preventive approaches that reduce disease incidence. Bioactive food 
components are increasingly being evaluated as potential chemopreventive agents 
(96, 97) . One such agent is resveratrol, a phytochemical which has been considered 
as a chemopreventive compound for human prostate cancer (5).  
 
Resveratrol is a polyphenol (3, 4, 5-trihydroxystilbene), categorized as 
phytoalexin, it is produced in plants exposed to environmental stress or pathogenic 
attack (98), and it is found principally in the skin of grapes, peanuts and other plant 
species (99). Red wine contains 1-10 mg of resveratrol/L (4-40 µM; 100). Published 
studies suggest that resveratrol may inhibit all three major stages of carcinogenesis: 
initiation, promotion, and progression (7, 99). At the molecular level, resveratrol was 
shown to possess antioxidant property (101) and anti-inflammatory property (8), and 
is weakly estrogenic (100).  
 
Additional studies are needed to assess the potential usefulness of resveratrol 
in treating or preventing human prostate cancer. In particular, its mechanism of action 




(85, 102), inhibits DNA synthesis (88), and increases apoptosis in LNCaP cells (89). 
It has been suggested that resveratrol may increase expression and serine 
phosphorylation of p53 (103), thus activating p53-dependent signaling.  Resveratrol 
also decreases expression of PSA (85). This result suggests that the effects of 
resveratrol may be mediated by the AR. AR is a member of the nuclear receptor super 
family  that mediates the cells response to androgenic hormones (104). The 
androgen/AR complex binds to AREs in the promoter region of target genes and 
cooperates with coactivators to facilitate transcription of ARGs. ARGs such as PSA 
play important cellular functions including cell cycle regulation, transcription, cell 
proliferation, differentiation, and metabolism (105, 106). The overall effect of 
androgens is proliferative and anti-apoptotic, and exposure to androgens is considered 
as a risk factor for prostate cancer (107).  
 
The present study tests the hypothesis that resveratrol affects multiple 
pathways to impact prostate cancer development, and the aspects of many resveratrol 
effects are mediated partly by AR- or ER- dependent signaling. Our experimental 
results support this hypothesis. Furthermore, we showed that resveratrol has selective 





3.3 Materials and Methods  
3.3.1 Chemicals 
Resveratrol, 17β-estradiol, and dimethylsulfoxide (DMSO) were from Sigma 
Chemical Co. (St. Louis, MO). The R1881, a synthesized androgen, was from NEN 
Life Science Products (Boston, MA).  The pure antiestrogen ICI 182,780 was from 
Tocris Cockson, Inc. (Ellisville, MO). 
 
3.3.2 Cells and Cell Culture 
LNCaP human prostate cancer cells were obtained from the American Type 
Culture Collection (Manassas, VA) and maintained in Media A (RPMI 1640 medium 
(Invitrogen, Carlsbad, CA), 2 mM L-glutamine (Sigma), 100 U/mL penicillin and 100 
µg/mL streptomycin (BioSource International, Camarillo, CA)) containing 10% fetal 
bovine serum (FBS) (Invitrogen, Carlsbad, CA). Cells were incubated in the presence 
of 5% CO2 in air at 37 ˚C. LNCaP cells were cultured at 1x106 cells/well in 6-well 
plates for gene expression studies and at 5x104 cells/well in 24-well plates for 
sulforhodamine B (SRB) assay. 
 
3.3.3 Cell Growth Assay 
Cell growth was analyzed using the SRB assay as described previously (108). 
LNCaP cells (5x104 cells/well) were treated with 0 (vehicle, DMSO), 1, 5, 10, 25, 50 
µM resveratrol for 0-96 hours in 24-well plates (Costar). The medium was replaced 




experiments with R1881 or  E2, cells were switched to media B (RPMI 1640 medium 
without phenol red, 2 mM L-glutamine (Sigma), 100 U/mL penicillin and 100 µg/mL 
streptomycin) with 10% CDS (Charcoal Dextran-treated FBS; Hyclone, Logan, UT) 
24 hours after plating to minimize the effect of serum hormones.  
 
3.3.4 ARG Expression in Cultured Cells  
LNCaP cells were plated in 6-well plates (1.0 x 106 cells/well) and switched to 
media B with 10% CDS 24 hours after plating cells to minimize the effect of serum 
hormones. Twenty-four hours later, we exchanged fresh media containing 1 nM 
R1881 or E2 with or without 25 µM resveratrol or 10 µM ICI 182,780. Fresh media 
with test compounds were added after 24 hours and cells were harvested after 48 
hours in the presence of test compounds. For time course experiments, samples were 
taken up to 72 hours and RNA was harvested every 24 hours using the Trizol method 
(Invitrogen). Messenger RNA of ARGs was quantified by TaqMan real-time PCR as 
described previously (109). Briefly, 1 microgram of total RNA was reverse-
transcribed using the Stratascript First Strand cDNA Synthesis Kit (Stratagene, La 
Jolla, CA). RT-PCR was then performed using the TaqMan universal PCR Master 
mix (Applied Biosystems, Foster City, CA) on an ABI Prism 7000 thermocycler 
(Applied Biosystems) following the manufacturer’s protocol. Each 25 μl PCR 
reaction contained 2.5 μl of cDNA. Results were calculated relative to untreated 
control using the Ct method as described in the manufacturer’s protocol. All 




3.3.5 Western Blot Analysis 
LNCaP cells were plated on a 100 mm Falcon tissue culture plate 
(2x106cells/plate) in media A containing 10% FBS. After 24 hours, the media were 
changed to media B with 10% CDS and the cells were incubated for an additional 24 
hours. After the incubation, the cells were then treated with either 1 nM R1881 or 1 
nM E2 in the presence or absence of 25 µM resveratrol. Media containing the test 
compounds were replaced every 24 hours. Cells were treated with the test compounds 
for 96 hours. After treatment the cells were washed once with Phosphate Buffered 
Saline (PBS, pH 7.4) and harvested into a 1.5-mL micro-tube with a RIPA buffer 
(Santa Cruz Biotechnology, Santa Cruz, CA) following the manufacturer’s protocol. 
The protein concentration of cell lysate was determined by DC® protein assay 
(BioRad, Richmond, CA). Lysate protein (60 µg) was separated on Ready Gel® 
precasted gels (10 well, 15 %  resolving Tris-HCl, Bio-Rad, Hercules, CA) and 
transferred to an Immobilon PVDF membrane (Millipore, Bedford, MA) according to 
Bio-Rad’s protocol. For immunodetection, the membrane was blocked in blocking 
buffer (1xPBS/Casein Blocker containing 0.1% Tween 20, Bio-Rad, Hercules, CA) 
for 2 hours at room temperature. The membrane was then washed four times (5 min 
each) with washing buffer (1x PBS containing 0.1% Tween 20). It was then incubated 
at 4 oC overnight with primary rabbit antibody for PSA (Santa Cruz Biotechnology, 
Santa Cruz, CA) at a 1:10,000 dilution in blocking buffer. After primary antibody 
incubation, the membrane was washed four times (3 times at 5 min each and one time 
for 15 min) with washing buffer. Subsequently, the membrane was incubated for 2 
hours at room temperature with anti-rabbit horseradish peroxidase secondary 




buffer. After secondary antibody incubation, the membrane was washed with washing 
buffer for four times (5, 5, 10 and 15 min each) and visualized using SuperSignal 
West Dura Extended Duration Substrate (Pierce, Rockford, lL) following the 
manufacturer’s instructions.  The image detection is used the Sensicam CCD camera 
(Cooke Cooperation, Eugene, OR) with LabWorks software and integrated into the 
Epi Chemi II imaging workstation from UVP (UVP, Upland, CA).  
 
3.3.6 Statistics  
StatView (SAS Institute Inc., Cary, NC) software was used for statistical 
analysis. Multiple group data were analyzed using ANOVA followed by post-hoc 
analysis with Fisher’s PLSD test. The unpaired Student’s t-test was used to compare 
experiments within two groups. Values were considered significant when p<0.05.  
 
3.4 Result 
3.4.1 Effects of Resveratrol on LNCaP Cell Growth 
This study examines the effects of resveratrol on growth and gene expression 
in human LNCaP prostate cancer cells in vitro. LNCaP cells were cultured in the 
presence of 10% FBS and 0, 1, 5, 25 or 50 µM resveratrol for 0-96 hours. Cell 
number was defined as the description in Materials and Methods. Growth inhibition 
was concentration- and time-dependent at concentrations below 50 µM or time points 
shorter than 96 hours and growth was significantly inhibited at concentrations as low 




hours at 50 μM. When treated the LNCaP with 25 μM resveratrol, we can see the 
inhibition after 72 hours.   
 
3.4.2 Effects of Resveratrol on p53-dependent Pathway 
Previous studies suggested that the effects of resveratrol may be mediated by 
p53 or p53 –dependent processes (89). Here, this idea was tested by examining 
expression of p21 mRNA, which is tightly regulated by p53 (103). Figure 3 shows 
time and dose-dependent measurements of p21 mRNA in LNCaP cells exposed to 
resveratrol. The results show that p21 mRNA increases significantly after 24 hours 
exposure to 25 µM resveratrol, but not at lower resveratrol concentrations (Figure 3C). 
At 25 µM, resveratrol significantly induces p21 mRNA by 24 hours and the level of 







































































































































Figure 3.  Effect of resveratrol on cell growth. LNCaP cells were treated with a vehicle (DMSO) or 
resveratrol for 0-96 hours in a medium containing 10% FBS. Cell growth was measured by the SRB 
assay. Values are expressed as mean ±SD. Asterisks indicate statistical significance using ANOVA 
followed by post-hoc analysis (p<0.05). (A) Cells were grown in the presence of the indicated 
concentration of resveratrol and aliquots were taken at 24 hours intervals from 0 to 96 hours for 
measurement of A530.  (B) Cells were grown in the presence of 0, 1, 5, 10, 25 or 50 µM resveratrol and 
incubated for 96 hours. (C) LNCaP cells were treated with 0 (vehicle control), 1, 5, or 25 µM 
resveratrol for 0-72 hours, total RNA isolated and analyzed for p21 mRNA by real-time PCR. Values 
are expressed as mean ±SD. Letters indicate statistical significance using ANOVA followed by post-
hoc analysis (p<0.05). Cells were grown in the presence of the indicated concentration of resveratrol 
for 72 hours. (D) Cells were grown in the presence of 25 µM resveratrol and aliquots were taken at 24 




3.4.3 Differential Effects of Resveratrol on Expression of Androgen-
Responsive Genes 
Because resveratrol inhibits growth of LNCaP cells at 10 µM, which is lower 
than the apoptosis inducing concentration, additional mechanism maybe involved in 
order to explaining this phenomenon. Given growth of the prostate cancer cells 
required androgen (110), we hypothesized that resveratrol may act through 
modulation of   androgen-mediated events to inhibit the LNCaP cell growth when 
treated the cells in 10% FBS. Furthermore, resveratrol might act as an anti-androgenic 
compound to inhibit the androgen-responsive effects. This idea was tested by 
measuring an expression of four androgen-responsive genes (ARGs): prostate specific 
antigen (PSA), Ste20-related Proline-Alanine rich Kinase (SPAK), β-2 
microglobulin (B2M) and Selenoprotein P (SEPP1; 105) in LNCaP cells exposed to 
resveratrol. Cells were grown in 10% FBS and treated with 25 µM resveratrol for 48 
hours. Figure 4A shows that resveratrol inhibits expression of PSA and SPAK under 
these conditions. More detailed analysis shows that resveratrol inhibits expression of 
SPAK in a dose- and time-dependent manner (Figure 4B) and at concentrations as 
low as 5 µM. In contrast, resveratrol has no significant effect on the expression of 
B2M and SEPP1 (Figure 4C). However, different results were observed when cells 
were cultured in 10% CDS, which is depleted of serum factors including steroid 
hormones. Under these conditions, moderate or no reduction of PSA (Figure 5A) and 
SPAK mRNA (Figure 5B) is observed after incubation in the presence of 25 µM 




expression may be modulated by the presence or absence of hormonal factors other 














































































































                                                   
 
 
Figure 4. Effects of resveratrol on ARGs in LNCaP cells cultured in media containing 10% FBS. 
LNCaP cells were treated with 25 µM resveratrol for 48 hours, total RNA was isolated and relative 
mRNA expression of ARGs was measured by real-time PCR. Values are normalized to control cells 
and expressed as mean ±SD. (A) Expression of PSA and SPAK. (B) Cells were incubated in the 
presence of 0, 1, 5, or 25µM resveratrol and aliquots were taken at 24 hours intervals from 0 to 72 
hours. SPAK mRNA was quantified by PCR. (C) Expression of B2M and SEPP1. Asterisk indicates 






















































Figure 5. Effects of resveratrol on ARGs in LNCaP cells cultured in media containing 10% CDS. 
LNCaP cells were treated with 25 µM resveratrol for 48 hours, total RNA isolated and relative mRNA 
expression of PSA or SPAK was measured by real-time PCR. Values are normalized to control cells 
and expressed as mean ±SD. (A) PSA; (B) SPAK. Asterisk indicates that values are significantly 











3.4.4 Resveratrol Inhibits Synthetic Androgen R1881-induced Gene 
Expression 
If the effect of resveratrol on ARGs is modulated by hormones, then it may 
act through the androgen-response pathway, which is critical for prostate cancer cell 
growth. This possibility was examined by growing cells in 10% CDS in the presence 
of R1881, induces ARG expression, and then determining the impact of exposure to 
resveratrol. Figure 6A shows that the mRNA expression all four ARGs, PSA, SPAK, 
B2M, and SEPP1, are significantly induced by R1881, but PSA and SPAK are 
induced more strongly than B2M and SEPP1 at mRNA level. Under these conditions, 
25 µM resveratrol inhibits mRNA expression of PSA, SPAK, B2M, and SEPP1. To 
correlate the transcriptional effect with protein expression, we examine the effect of 
resveratrol on PSA expression, as illustrated in Figure 6B, resveratrol inhibited the 
R1881-induced PSA expression as what we found in the result of mRNA.  
 
3.4.5 Effects of Resveratrol on R1881-induced Cell Growth in LNCaP 
Cells  
To correlate the effects on ARG mRNA and protein to cell growth end point, 
we also examine if resveratrol also inhibits androgen-stimulated cell growth. LNCaP 
cells were plated in 10% CDS with 1 nM R1881 and 0, 1, 25 or 50 µM resveratrol. 
The results show that resveratrol inhibits cell growth induced by R1881 in a 
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Figure 6. (A) Effects of resveratrol on R1881 inducted mRNA expression of ARGs in LNCaP cells. 
LNCaP cells were treated with R1881 in presence or absence of 25 µM resveratrol for 48 hours in 
media containing 10%CDS, total RNA isolated and relative mRNA expression of ARGs was measured 
by real-time PCR. Values are normalized to control cells and expressed as mean ±SD. Letters indicate 
values that are significantly different from control using ANOVA followed by post-hoc analysis 
(p<0.05). (B) Western blot result of inhibitory effects of resveratrol on R1881 and E2 induction of PSA 
in LNCaP cells. Lane 1: control, treated with DMSO; Lane 2: 25 µM resveratrol; Lane3: 1 nM R1881; 
Lane 4: 1 nM R1881+25 µM resveratrol; Lane 5: 1 nM E2; Lane 6: 1 nM E2+25 µM resveratrol. 
LNCaP cells were treated for 96 hours. (C) Inhibitory effects of resveratrol on R1881 induced LNCaP 
cell grwoth. LNCaP cells were treated with/without R1881 and 0 (vehicle), 1, 25, 50 μM resveratrol 
for 96 hours in 10% CDS medium. Cell growth was measured by the SRB assay. Values are expressed 
as mean ±SD. Letters indicate values that are significantly different using ANOVA followed by post-





3.4.6 Resveratrol Inhibits ARGs mRNA Level Induced by E2 in 10% 
CDS 
Previous studies showed that E2 stimulates expression of PSA and that the 
phytoestrogen, genistein, also influences ARG expression in LNCaP cells (91). This 
suggested that estrogen-mediated events might also play a role in the effects of 
resveratrol on ARGs in LNCaP cells treated in 10% FBS. This idea was examined by 
growing LNCaP cells in 10% CDS with or without E2 in the presence or absence of 
25 µM resveratrol. Figure 7 shows that E2 induces expression of PSA (A), but not 
SEPP1 (B), and this effect of E2 can be blocked by resveratrol or the anti-estrogen 
ICI 182,780. Consistent with mRNA results, at the protein level PSA protein 
expression was also induced by E2 and inhibited by resveratrol (Figure 7B). Similar 
to R1881, resveratrol also inhibits estradiol-stimulated growth of LNCaP cells. Figure 
7C shows that 1 nM E2 stimulates LNCaP cell growth by approximately 2-fold, but 5 
µM or higher resveratrol inhibits this effect. Resveratrol inhibits E2-stimulated cell 
growth in a dose-dependent manner from 1 to 50 µM. A significant effect can be 
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Figure 7. Inhibitory effects of resveratrol and ICI 182,780 on estrogen induction of ARGs in LNCaP 
cells cultured in media containing 10% CDS. LNCaP cells were treated with E2 (1nM) in presence or 
absence of 25 μM resveratrol or 10 μM ICI 182,780 for 48 hours, total RNA isolated and relative 
mRNA expression of ARGs was measured by real-time PCR. Values are normalized to control cells 
and expressed as mean ±SD.  (A) PSA. (B) SPAK. Letters indicate values that are statistically 
significant using ANOVA followed by post-hoc analysis (p<0.05). (C) Inhibitory effects of resveratrol 
on estrogen- induced LNCaP cell growth. LNCaP cells were treated with vehicle or with E2 in 
presence of 0 (vehicle), 1, 25, 50 µM resveratrol for 96 hours in media containing 10% CDS. Cell 
growth was measured by the SRB assay as described in materials and methods. Values are expressed 
as mean ±SD. Letters indicate values that are significantly different from control using ANOVA 





This study examines the effects of resveratrol on growth and gene expression 
in the androgen-responsive prostate cancer cell, LNCaP. The results suggest that 
resveratrol, a phytochemical with the potential as a chemopreventive agent, 
modulates hormonally-regulated cell growth and gene expression.  
 
Data presented here show a novel effect of resveratrol on the expression of 
androgen-regulated genes. In particular, when grown in the presence of 10% FBS, 
resveratrol inhibits the expression of PSA and SPAK, but not B2M and SEPP1 
(Figure 4).  To our knowledge, this is the first demonstration that resveratrol 
differentially alters the expression of ARGs in LNCaP cells. This effect seems to be 
due to the differential responses of these genes to the steroid hormones, androgen and 
estrogen.  In steroid hormone-deprived condition, R1881 induces the expression of 
PSA, SPAK, B2M and SEPP1 in LNCaP cells, and resveratrol blocks this androgen-
dependent expression in all cases. By contrast, E2 can stimulate the expression of 
PSA in 10% CDS (Figure 7A), but not the expression of SEPP1 (Figure 7B). Thus, 
the lack of inhibitory effects in cell culture in 10% FBS may be due in part to the 
presence of estradiol. These results support that the culturing condition may greatly 
affect molecular end points of resveratrol and interpret of the biological activity of 
resveratrol. Resveratrol may be a general inhibitor of androgen receptor-mediated 
events. For example, resveratrol strongly down regulates PSA, a well-known ARG 
and a marker for prostate cancer in clinical diagnosis (111). Although regulation of 
PSA by resveratrol has been documented (12, 92), little is known of the regulation of 




regulated gene whose function is not well known, we demonstrated that it is down 
regulated by resveratrol in a dose- and time- dependent manner (Figure 4B). In 
addition, we also showed the effect of resveratrol on ARG mRNA is correlated with 
protein levels. Our western blotting data showed that R1881-induced PSA protein 
level can be inhibited by resveratrol (Figure 6B), consistent with Hsieh et al. (12). 
The antibodies of SPAK, B2M, and SEPP1 can not find in the market or can not get 
the western blot concentrations, so we assume there is a linear relationship between 
protein and mRNA level.  Our research demonstrated resveratrol’s inhibition of 
androgen-stimulated growth of LNCaP cells (Figure 6C). In addition to an effect on 
an AR-mediated event, modulation of AR-mediated, lends further support to the 
event by resveratrol as a potential mechanism. We found resveratrol significantly 
inhibited R1881-induced the growth of LNCaP cell started at 1 μM. One microM is 
reachable in human’s body after oral intake 360 μg/ kg body weight of resveratrol. 
Other researches focused on the function of  higher concentration resvertrol, but in 
vivo study showed 75% of resveratrol is excreted via feces and urine (20), and very 
less resveratrol shows as free form (21). In human serum, the major form of 
resveratrol is trans-resveratrol glucuronides (21). For the future study, it will be 
necessary to know whether trans-resveratrol glucuronides also has the effect as free 
resveratrol does.   
 
Another novel observation was finding that resveratrol modulates estrogen-
stimulated events in LNCaP cells, as described above (Figure 7C). This is consistent 
with the fact that E2 may play an important role in normal prostate physiology and in 




and this effect, as well as the E2 induced cell proliferation, is inhibited by resveratrol 
(Figure 7B, C). Resveratrol is considered as a phytoestrogen and a mixed 
agonist/antagonist for estrogen receptor α and β (72, 113). Interestingly, at a 
concentration of 1 µM, resveratrol slightly induces expression of SPAK and may be 
acting as an ER agonist, while at 5 µM or higher, resveratrol acts as an antagonist and 
suppresses E2 induced transcription of SPAK (Figure 4B). This is same as what 
Matsumura et al. (114) found that resveratrol acts as an ER agonist at low 
concentration (~1 μM), but becomes an ER antagonist at higher concentration. 
 
In addition to AR and ER-mediated event, the inhibitory effect of resveratrol 
on prostate cancer cell growth may in part be mediated by p53 or p53-dependent 
events (103). This is consistent with our observation that 25 µM resveratrol induces 
p21 expression in LNCaP cells. There appears to be a threshold for resveratrol-
dependent activation of p21, because no activation was observed at lower doses. This 
may be relevant when considering pharmacological uses of resveratrol. In particular, 
it was reported that oral dosing of rats with 50 mg/kg resveratrol can lead to a plasma 
concentration of ≥10 µM resveratrol glycogen within 8 hours (101).  
 
Figure 8 presents a summary of our findings regarding the effects of 
resveratrol on prostate cancer growth. We propose that resveratrol exerts 
concentration-dependent effects on multiple cellular pathways. At low (~5 µM) 
concentration, resveratrol can modulate steroid hormone-mediated events including 
hormone-dependent gene expression. At higher concentration, additional responses 




resveratrol to inhibit cell growth and may explain the chemopreventive effects of 










































Figure 8. Summary of effects of resveratrol on LNCaP cell growth and gene expression. ARG: 












Chapter 4: Modulation of IGF-1 Pathway by Resveratrol in 
Human Prostate Cancer LNCaP Cells  
4.1 Abstract 
Resveratrol is a potential prostate cancer chemopreventive agent. This study 
examines modulation of IGF-1 pathway as a mechanism by which resveratrol may 
exert its molecular effect in LNCaP prostate cancer cells. Resveratrol suppressed the 
expression of IGF-1 and IGF-1R mRNA in LNCaP cells cultured in 10% FBS at 5 
μM. LNCaP cells cultured in the presence of R1881, a synthetic androgen, 
demonstrated induction of both IGF-1 and IGF-1R mRNA levels. This R1881-
induced expression of IGF-1 and IGF-1R mRNA were completely blocked by 
treatment of cells with 25 μM resveratrol. The estrogen, 17β-estradiol (E2), also 
induced transcription of IGF-1 and IGF-1R mRNA, but has less potent than the 
R1881. The effect of E2 on IGF-1 and IGF-1R mRNA was also partially inhibited by 
treatment of cells with 25 μM resveratrol. These results support the hypothesis that 
resveratrol may exert a effect on IGF-1 and IGF-1R mRNA in LNCaP cells through 
the modulation of both androgen- and estrogen-induced signaling pathways. 
 
4.2 Introduction 
The cytokine, insulin-like growth factor 1 (IGF-1), is required for normal 
growth of prostate (115). IGF-1 exerts its biological effect through receptor-mediated 




major receptor that interacts with IGF-1 in prostate cancer cells is the IGF-1R. IGF-
1R is a transmembrane tyrosine kinase that is widely expressed in many cell types. 
More importantly, IGF-1R is often over expressed in cancer cells (116). Recent 
epidemiological and experimental studies showed that IGF-1 also plays an important 
role in prostate carcinogenesis (117). High levels of IGF-1 in serums of humans were 
found to be associated with increased risk of prostate cancer (118). In addition, 
several groups reported that IGF-1 treatment can lead to enhancement of  the growth 
of prostate cancer cells regardless of their androgen dependency (117, 119).  Calorie 
restriction diet, which reduced serum IGF-1 level, appears to be associated with 
decreasing the risk of prostate cancer in humans (118), further supporting a role of 
IGF-1 in prostate carcinogenesis. Therefore, available literatures consistently support 
that IGF-1 may increase prostate cancer risk through increasing growth of cancer 
cells (79). However, the mechanism by which IGF-1 promotes prostate cancer 
remains still largely unknown.       
 
The male sex hormone, androgen, is required for normal prostate cell growth 
and development (106).  However, androgen is also known to be associated with 
prostate carcinogenesis (106). Androgen has been showed to up-regulate IGF-1R 
protein expression and sensitize prostate cancer cells to the biological effects of IGF-
1 (78). Moreover, IGF-1 is also known to modulate the AR-dependent process in 
normal and cancer human prostate cell lines (120, 121). Thus, the interaction between 
AR and IGF-1 pathways exists. In addition to androgen, female steroid hormone, 
estrogen, also stimulated the proliferation of the prostate (112). Previous study 




liver carcinoma cell line (122). IGF-1 has been shown to modulate the ER-dependent 
process (120) and activate ER-mediated gene transcription (123). Thus, similar to 
androgen, the interaction between ER and IGF-1 pathways also exists. However, the 
effect of estrogen on the IGF-1 pathway in prostate cells is not known. To test this, 
LNCaP cells were treated with 1 nM E2 in the presences or absence of 10 μM ICI 
182,780, a pure anti-estrogen. ICI 182,780 acts through competing with E2 binds with 
ER.  
 
Dietary factors are recognized as determinants of circulating IGF-1. For 
example, energy and/or protein deprivation markedly decrease serum IGF-1 
concentrations in human body (124). In our laboratory, previous data showed that the 
phytoestrogen, genistein, down-regulated IGF-1 and IGF-1R mRNA levels in 
microarray experiments (109). Both genistein and resveratrol are phytoestrogens, and 
share some similar effects on AR and ER mediated pathways as reported in chapter 3. 
Resveratrol has been showed to influence the IGF-1 expression in the human breast 
cancer by regulating IGF-1R mRNA (125). Hence, we hypothesized that the 
inhibitory effect of resveratrol on prostate cancer cell growth may in part occur 
through modulating the components of IGF-1 pathway. Furthermore, we proposed 
that resveratrol may exert its effect on IGF-1 and IGF-1R through both AR- and ER-





4.3 Materials and Methods 
4.3.1 Chemicals 
Resveratrol, E2, and dimethylsulfoxide (DMSO) were obtained from Sigma 
Chemical Co. (St. Louis, MO). The R1881, a synthesized androgen, was purchased 
from NEN Life Science Products (Boston, MA). The pure antiestrogen ICI 182,780 
was from Tocris Cockson, Inc. (Ellisville, MO). 
 
4.3.2 Cell and Cell Culture 
The LNCaP human prostate cancer cell lines were obtained from the 
American Type Culture Collection (Manassas, VA) and maintained in a RPMI 1640 
medium (Invitrogen, Carlsbad, CA) containing 10% FBS (Invitrogen), 2 mM L-
glutamine (Sigma), 100 U/ml penicillin and 100 μg/ml streptomycin (BioSource 
International, Camarillo, CA). Cells were incubated in the presence of 5% CO2 in air 
at 37 ˚C.  
 
4.3.3 Cell Culture for the Detection of IGF-1 and IGF-1R Gene 
Expression 
To assess the effect of steroid hormones and resveratrol on IGF-1 and IGF-1R 
gene expression, LNCaP cells were plated in six-well plates (0.5 x 106 cells/well). For 
the resveratrol-only experiment, the cells were cultured in 10% FBS in RPMI1640 





For androgen and estrogen experiments using R1881 and E2, respectively, the 
cells were switched to a RPMI 1640 medium without phenol red, with 10% Charcoal 
Dextran-treated FBS (CDS; Hyclone, Logan, UT) 24 hours after plating cells, to 
minimize the effect of serum hormones. The cells were incubated with 1 nM of 
R1881 or E2 either in the presence or absence of 25 µM resveratrol or 10 µM ICI 
182,780, and media were replaced with test compounds every 24 hours. After 48 
hours following addition of test compounds, the cells were harvested. RNA was 
isolated using Trizol (Invitrogen) according to the manufacturer’s instruction. 
Quantization of mRNA expression was performed using real-time PCR as described 
below. 
 
4.3.4 Semi-quantitative Determination of mRNA Levels. 
The TaqMan real-time RT-PCR method was used to quantify gene expression. 
Briefly, one microgram of total RNA was reverse-transcribed using the Stratascript 
First Strand cDNA Synthesis Kit (Stratagene, La Jolla, CA). RT-PCR was then 
performed using the TaqMan universal PCR Master mix (Applied Biosystems, Foster 
City, CA) on an ABI Prism 7000 thermocycler (Applied Biosystems) following the 
manufacturer’s protocol. Each 25 μl PCR reaction contained 2.5 μl of cDNA. Results 
were calculated relative to untreated control using the Ct method as described in the 
manufacturer’s protocol. All experiments were repeated three times and each PCR 
reaction was run in triplicate. Real-time PCR primers and probes for IGF-1 (GenBank 
accession No. NM_000618) and IGF-1R (GenBank accession No. NM_000875) were 




4.3.5 Statistical Methods 
For statistical analysis, StatView (SAS Institute Inc., Cary, NC) software was 
used. Multiple group data were analyzed using ANOVA followed by post-hoc 
analysis with Fisher’s PLSD test. The unpaired Student’s t-test was used to compare 
experiments within two groups. The significance level was set at p <0.05 in all cases. 
 
4.4 Results 
4.4.1 Resveratrol Inhibits the Expression of IGF-1 and IGF-1R mRNA 
in LNCaP Cells 
To test our hypothesis that resveratrol can modulate IGF-1 mediated pathways, 
we first asked whether resveratrol can affect the mRNA expression of IGF-1 and 
IGF-1R. We found treatment of LNCaP cells with resveratrol leads to inhibition of 
IGF-1 mRNA level (Figure 9). The inhibition of the IGF-1 mRNA level occurred at a 
does-dependent manner, with a significant effect of resveratrol on IGF-1 mRNA 
observed at 5 µM (Figure 9A). Resveratrol also exerts an effect on IGF-1R mRNA 
expression, but the effect of resveratrol on IGF-1R is different from that of IGF-1 
(Figure 9B). Exposure of LNCaP cells to 1 µM resveratrol leads to a significant 
increase in the expression of IGF-1R mRNA. However, at concentrations higher than 






































































Figure 9. Resveratrol inhibited the expression of IGF-1 (A) and IGF-1R (B) at the mRNA level. 
LNCaP cells were treated with 0, 1, 5, and 10 µM resveratrol for 72 hours; total RNAs were isolated 
and relative mRNA expressions of IGF-1 or IGF-1R were measured by real-time PCR as described in 
materials and methods. Values are normalized to control cells and expressed as mean ±SD. Asterisks 









4.4.2 Resveratrol Inhibited Androgen Induced IGF-1 and IGF-1R 
mRNA Level 
As mention in Introduction, androgen is known to induce IGF-1R mRNA 
expression in prostate cancer. Consistent with others finding (71), we also observed 
induction of IGF-1R mRNA by 1 nM R1881, a synthetic androgen (Figure 10). 
Moreover, we also observed induction of IGF-1 mRNA by R1881. To test our 
hypothesis whether resveratrol can affect IGF-1 and IGF-1R mRNA expression 
through modulation of androgen-dependent pathway, the effects of resveratrol on 
R1881-induced expressions of IGF-1 and IGF-1R mRNA were examined. LNCaP 
cells were exposed to 1 nM R1881 in presence or absence of 25 µM resveratrol for 48 
hours as described in Materials and Methods. As shown in Figure 10A, treatment 
with 25 μM resveratrol completely abolished the induction of IGF-1 mRNA by 
R1881. In addition, treatment of LNCaP cells with 25 µM resveratrol also completely 































































































































Figure 10. Effect of Resveratrol (Res) on R1881 induction of IGF-1 (A) and IGF-1R (B) mRNA levels. 
LNCaP cells were treated with R1881 in the presence or absence of 25 µM resveratrol for 48 hours in 
media containing 10%CDS; total RNA isolated and relative mRNA expression of IGF-1 and IGF-1R 
were measured by real-time PCR as described in Materials and Methods. Values are normalized to 
control cells and expressed as mean ±SD. Letters indicate values that are significantly different from 











4.4.3 E2 Induced IGF-1 and IGF-1R mRNA Level in LNCaP 
In addition to androgen, estrogen has been showed to induce the mRNA 
expression of IGF-1 in liver cancer cells (105). We first tested whether IGF-1 and 
IGF-1R mRNA are modulated by estrogen in prostate cancer cells. As showed in 
Figure 11A, treatment of LNCaP cells with E2 (1nM) leads to induction of IGF-1 
mRNA. Moreover, exposure to E2, also leads to increase in IGF-1R mRNA (Figure 
11B). To determine if the effect of E2 is through an ER-mediated event, the effects of 
the pure anti-estrogen ICI 182,780 on E2-induction of IGF-1 and IGF-1R were 
examined. As shown in figure 11A, the E2 induced the expression of IGF-1 mRNA in 
LNCaP cells, was completely inhibited by ICI 182,780 (Figure 11A). Similarly, the 
E2 induced the expression of IGF-1R mRNA was also inhibited by treatment with 10 
μM ICI 182,780 (Figure 11B).  
 
4.4.4 Resveratrol Inhibited Estrogen Induced IGF-1 and IGF-1R mRNA 
Level 
Since IGF-1 and IGF-1R both modulate by E2, we also considered whether 
the effect of resveratrol observed in Figure 9 may be due in part to an effect on the 
E2-mediated pathway. The cells were exposed to 1 nM E2 in the presence or absence 
of 25 μM resveratrol for 48 hours, and the expression of IGF-1 and IGF-1R mRNA 
were determined as described in Materials and Methods. As showed in Figure 12A, 
resveratrol significantly inhibited the E2-induced increase in IGF-1 mRNA. Similarly, 
as shown in Figure 12B, treatment with resveratrol also significantly inhibited the E2-














































































































Figure 12. Inhibitory effects of resveratrol on E2 induction of (A) IGF-1 and (B) IGF-1R mRNA in 
LNCaP cells. LNCaP cells were treated with E2 (1nM) in the presence or absence of 25 μM resveratrol 
for 48 hours; total RNA isolated and relative mRNA expression of ARGs was measured by real-time 
PCR. Values are normalized to control cells and expressed as mean ±SD. Letters indicate values that 











The present study provided experimental data to support the hypothesis that 
resveratrol’s inhibition of prostate cancer growth may involve modulation of the IGF-
1-mediated pathway. As shown in Figure 9, treatment of LNCaP cells with resveratrol 
leads to inhibition of the mRNA expression of both IGF-1 and IGF-1R started at 5 
μM. Given the growth promotional effect of IGF-1 on LNCaP cells (126), modulation 
of IGF-1 and IGF-1R may contribute to the resveratrol growth inhibitory effect on 
LNCaP. The effects of resveratrol on IGF-1 and IGF-1R appeared to be due to 
inhibition of both androgen, as well as estrogen -mediated event. This is supported by 
inhibition of androgen and estrogen induction of IGF-1 and IGF-1R by resveratrol.  
 
The mechanism, resveratrol acts to inhibit the androgen-induced increase of 
IGF-1R, may involve signal transduction pathway mediated by Src/ERK (MAP 
Kinase cascades). Consistent with our results, Pandini et al. (78) have also reported 
that the synthetic androgen R1881 induced the IGF-IR expression in AR-positive 
prostate cancer cells LNCaP. In accordance with IGF-IR up-regulation by androgen, 
LNCaP cells were sensitized to the mitogenic effect of IGF-I, but this did not occur in 
AR-negative prostate cancer cells PC3. Pandini et al. (78)  further demonstrated that 
androgen-induced IGF-IR up-regulation involves the activation of the Src-
extracellular signal-regulated kinase pathway, because it was inhibited by both the Src 
inhibitor and the MEK-1 inhibitor. Hence, it is possible that our observed inhibitory 
effect of resveratrol on androgen induced-IGF-1R may involve modulation of 




In addition to confirm the effect of androgen on IGF-1R, we also observed a 
role for E2 on regulation of IGF-1R, a novel observation. Umayahara et al. (122) 
have found that estrogen induced IGF-1 transcription in HepG2 cell, but there is no 
research found that estrogen can regulate the expression of IGF-1R.  As shown in 
Figure 11, E2 also can up-regulate the mRNA expression of IGF-1 and IGF-1R in 
prostate LNCaP cells. The effects of E2 on IGF-1 and IGF-1R were completely 
inhibited by the pure antiestrogen, ICI 182,780, supporting the effects of E2 are 
mediated through ER-dependent events. Given that IGF-1 promotes LNCaP growth, 
induction of IGF-1 and IGF-1R by E2 may in part contribute to E2 growth promotive 
effect on LNCaP cells.  
 
As shown in Figure 12, we found resveratrol partially inhibited the mRNA 
expression of IGF-1 and IGF-1R induced by E2. This effect of resveratrol may be 
through modulation of ER-dependent events. In a study of phytoestrogen, Mueller et 
al. (127) found resveratrol is a weak agonist of both ERα and ERβ, but at high dose, 
100 μM, resveratrol becomes the antagonist to both ERα and ERβ. This is consistent 
with what we have found as illustrated in Figure 9, resveratrol induced the mRNA 
expression of IGF-1R at low the concentration (1μM), but inhibit the mRNA 
expression of IGF-1R occurred with increasing concentration of resveratrol.  
 
IGF-1 is known to stimulate proliferation, induce the metastasis, and decrease 
the apoptosis in cells (128). Based on this, IGF-1 pathway in prostate cancer cell 
appeared to subject to the regulation by androgen and E2. As mentioned above, 




growth inhibitory effect of resveratrol may be mediated through this mechanism. We 
further reason that resveratrol may inhibit the prostate cancer growth and metastasis 
in vivo by decreasing the expression of IGF-1 and IGF-1R. Additional study is 
necessary to support this hypothesis. After feeding 50 mg/Kg body weight in rats, the 
concentration of resveratrol can reach 6.6 μM. The physiological concentration of 
resveratrol seems can inhibit the LNCaP cell growth through inhibition of IGF-1 and 
IGF-1R.   
 
In summary, in this study, we found that in addition to androgen, estrogen also 
modulates the IGF-1 and IGF-1R mRNA expression through an ER-dependent 
pathway. We also found that resveratrol can inhibit the expression of IGF-1 and IGF-
1R mRNA. These effects on IGF-1 pathways appeared to be through modulation of 
both androgen- and estrogen-mediated pathways. These results provide a potential 






Chapter 5:  Future Study 
 
The precise mechanism underlying the cancer preventive effect of 
phytochemicals, in general, remains largely unknown. This thesis attempted to 
address this question and focused on the effect of resveratrol, a candidate prostate 
cancer preventive phytochemical. The results presented in this thesis show that 
resveratrol can inhibit the growth of prostate LNCaP cancer cells. The effect of 
resveratrol appeared to be correlated with modulation of multiple hormone/ cytokine 
pathways. These included androgen, estrogen, and IGF-1- mediated pathways. Our 
results provided information on the molecular targets (i.e. ARGs, IGF-1R) for 
resveratrol in prostate cancer cells and established the foundation that allows for 
further testing of resveratrol’s prostate cancer preventive potential. Further studies at 
in vivo level can be designed to test whether the pathway affected by resveratrol in 
vitro can lead to the prevention of tumor progression. These experiments can be 
conducted by using xenograft prostate cancer cell model or animal models to develop 
spontaneous prostate cancer, such as the transgenic adenocarcinoma mouse prostate 
(TRAMP) model (129). Future studies may also involve elucidation of the 
mechanisms by which resveratrol affects the AR pathway. One potential approach 
could be to examine if resveratrol affects SRC/ERK-mediated events. This may shed 
light on how resveratrol’s inhibition of androgen induction of ARGs, IGF-1 and IGF-
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